Metagenomi Therapeutics, Inc. (NASDAQ:MGX)
| Market Cap | 36.91M-69.3% |
| Revenue (ttm) | 13.56M-59.8% |
| Net Income | -93.46M-7.3% |
| EPS | -2.49-5.5% |
| Shares Out | 37.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 53,917 |
| Open | 1.00 |
| Previous Close | 0.98 |
| Day's Range | 0.96 - 1.00 |
| 52-Week Range | 0.96 - 3.95 |
| Beta | 0.70 |
| Analysts | Buy |
| Price Target | 14.50(+1379.14%) |
| Earnings Date | Nov 10, 2026 |
Metagenomi Therapeutics, Inc. has a live Insider Score.
Scored on 2 qualifying trades from 1 insider in the last 90 days.
About MGX
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$MGX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MGX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MGX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MGX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
MGX Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Facilities and overhead costs | $6.97M | 63.17% |
| Professional services and consulting | $2.46M | 22.32% |
| Interest and other | $1.29M | 11.69% |
| Affini-T | $286.00K | 2.59% |
| Other | $25.00K | 0.23% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New MGX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MGX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MGX
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $874.86K |
| VXFVanguard Extended Market ETF | $372.24K |
| IWCiShares Micro-Cap ETF | $89.07K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $40.00K |
Estimated from each fund’s disclosed top holdings × AUM
MGX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from MGX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score